Leap Therapeutics (LPTX) Competitors $0.35 -0.02 (-4.07%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. APLT, KRON, BLUE, BYSI, GANX, ONCY, NBRV, PDSB, ACRV, and SKYEShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Applied Therapeutics (APLT), Kronos Bio (KRON), bluebird bio (BLUE), BeyondSpring (BYSI), Gain Therapeutics (GANX), Oncolytics Biotech (ONCY), Nabriva Therapeutics (NBRV), PDS Biotechnology (PDSB), Acrivon Therapeutics (ACRV), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Applied Therapeutics Kronos Bio bluebird bio BeyondSpring Gain Therapeutics Oncolytics Biotech Nabriva Therapeutics PDS Biotechnology Acrivon Therapeutics Skye Bioscience Leap Therapeutics (NASDAQ:LPTX) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment. Do insiders and institutionals hold more shares of LPTX or APLT? 30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 5.4% of Leap Therapeutics shares are held by insiders. Comparatively, 8.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has stronger valuation & earnings, LPTX or APLT? Leap Therapeutics has higher revenue and earnings than Applied Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$81.41M-$1.84-0.20Applied Therapeutics-$212K-173.44-$119.76M-$1.61-0.20 Does the media refer more to LPTX or APLT? In the previous week, Applied Therapeutics had 3 more articles in the media than Leap Therapeutics. MarketBeat recorded 5 mentions for Applied Therapeutics and 2 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 0.29 beat Applied Therapeutics' score of -0.19 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Leap Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor LPTX or APLT? Leap Therapeutics received 214 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 68.37% of users gave Leap Therapeutics an outperform vote while only 57.55% of users gave Applied Therapeutics an outperform vote. CompanyUnderperformOutperformLeap TherapeuticsOutperform Votes29468.37% Underperform Votes13631.63% Applied TherapeuticsOutperform Votes8057.55% Underperform Votes5942.45% Which has more volatility & risk, LPTX or APLT? Leap Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500. Do analysts prefer LPTX or APLT? Leap Therapeutics currently has a consensus price target of $4.92, suggesting a potential upside of 1,218.14%. Applied Therapeutics has a consensus price target of $6.10, suggesting a potential upside of 1,830.38%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Leap Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is LPTX or APLT more profitable? Leap Therapeutics' return on equity of -116.24% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -116.24% -93.18% Applied Therapeutics N/A -260.75%-76.04% SummaryApplied Therapeutics beats Leap Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.10M$6.27B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.196.6921.6917.68Price / SalesN/A222.71373.7492.91Price / CashN/A65.6738.1534.64Price / Book0.165.776.363.94Net Income-$81.41M$142.01M$3.20B$247.45M7 Day Performance18.04%5.79%3.92%3.17%1 Month Performance-12.19%-15.47%-10.36%-8.53%1 Year Performance-87.57%-10.99%10.42%0.31% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics1.7649 of 5 stars$0.35-4.1%$4.92+1,288.9%-87.6%$14.61MN/A-0.1840Short Interest ↑Gap DownAPLTApplied Therapeutics3.8372 of 5 stars$0.41-5.7%$6.10+1,387.8%-94.1%$47.71M$-212,000.00-0.2530Earnings ReportGap UpKRONKronos Bio3.4909 of 5 stars$0.77-1.1%$1.63+110.9%-19.3%$46.98M$9.85M-0.54100Short Interest ↓Positive NewsGap DownBLUEbluebird bio2.6133 of 5 stars$4.77-3.6%$44.60+835.0%-79.0%$46.70M$83.81M-0.13520News CoverageBYSIBeyondSpringN/A$1.15-14.2%N/A-30.0%$46.36M$1.88M0.0080Gap DownHigh Trading VolumeGANXGain Therapeutics3.0542 of 5 stars$1.65flat$8.20+397.0%-44.9%$45.85M$50,000.00-1.5020Positive NewsONCYOncolytics Biotech2.0352 of 5 stars$0.53+6.5%$4.33+721.3%-47.4%$45.60MN/A-1.9530NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PDSBPDS Biotechnology1.5453 of 5 stars$0.96+1.4%$9.00+834.4%-62.9%$43.73MN/A-0.8320Short Interest ↓ACRVAcrivon Therapeutics1.9898 of 5 stars$1.39-7.9%$23.17+1,566.7%-80.5%$43.58MN/A-0.5158Short Interest ↑Gap DownSKYESkye Bioscience1.0568 of 5 stars$1.39+6.9%$18.00+1,195.0%-89.8%$43.06MN/A-1.9311Analyst Revision Remove Ads Related Companies and Tools Related Companies Applied Therapeutics Alternatives Kronos Bio Alternatives bluebird bio Alternatives BeyondSpring Alternatives Gain Therapeutics Alternatives Oncolytics Biotech Alternatives Nabriva Therapeutics Alternatives PDS Biotechnology Alternatives Acrivon Therapeutics Alternatives Skye Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LPTX Stock Free LPTX Stock Alerts